ArticleBioinformation2025
Serum Nogo - A as a predictor of neurological recovery in spinal cord injury.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neural stem cell-derived extracellular vesicles drive early neuroprotective and anti-apoptotic responses in spinal cord injury organotypic slices.Frontiers in cellular neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal Cord Injury (SCI) leads to severe neurological impairment due to irreversible damage to spinal axons and limited Spinal Cord Injury (SCI) causes severe neurological impairment due to irreversible axonal damage and limited regenerative capacity. Current treatments, including surgical decompression and neuroprotective agents, have limited effectiveness, with no consensus on the optimal therapeutic combination. Anti-Nogo-A therapies show promise in preclinical studies, but their clinical efficacy remains uncertain. Emerging evidence suggests that serum Nogo-A levels may serve as prognostic biomarkers for neurological recovery in SCI patients. This study explores the potential of targeting the Nogo A/Nogo receptor pathway to enhance axonal regeneration and support the development of personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.